Preclinical effects of melanocortins in male sexual dysfunction.
about
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy.Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link.The role of ghrelin signalling for sexual behaviour in male mice.Metabolic syndrome and lower urinary tract symptoms: the role of inflammation.Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
P2860
Preclinical effects of melanocortins in male sexual dysfunction.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Preclinical effects of melanocortins in male sexual dysfunction.
@ast
Preclinical effects of melanocortins in male sexual dysfunction.
@en
type
label
Preclinical effects of melanocortins in male sexual dysfunction.
@ast
Preclinical effects of melanocortins in male sexual dysfunction.
@en
prefLabel
Preclinical effects of melanocortins in male sexual dysfunction.
@ast
Preclinical effects of melanocortins in male sexual dysfunction.
@en
P2860
P356
P1476
Preclinical effects of melanocortins in male sexual dysfunction.
@en
P2093
A M Shadiack
P2860
P2888
P356
10.1038/IJIR.2008.17
P478
20 Suppl 1
P577
2008-07-01T00:00:00Z
P5875
P6179
1031792809